MEDIBIO APPOINTS NEW BOARD MEMBERS AND ESTABLISHMENT OF A GROWTH & ADVOCACY ADVISORY BOARD
● Mr. Michael Phelps and Mr. Patrick Kennedy have tendered their resignations as Non-Executive Directors of Medibio Limited effective 29 August 2019 as part of a planned transition to a newly formed Growth & Advocacy Advisory Board which will enable them to take a more active role in public awareness and advocacy for Medibio.
● Dr. Franklyn Prendergast, MD, also has tendered his resignation as Non-Executive Director of Medibio effective 29 August 2019 due to personal and other business obligations.
● The Board of Directors, as part of a thorough review of necessary skills, background and expertise to guide Medibio forward with its business and commercial strategies has appointed Ms. Lisa Wipperman Heine, Dr. Lisa Ragen Ide, and Ms. Liwanag Ojala as new Non-Executive Directors
effective 29 August 2019.
Melbourne, Australia and Minneapolis, MN – 29 August 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCB: MDBIF), a health technology company is pleased to announce the appointment of three superbly qualified individuals as new Non-Executive Directors: Ms. Lisa Wipperman Heine, Dr. Lisa Ragen Ide and Ms. Liwanag Ojala. Simultaneously, to make room for the new Directors, the Company also announces that it has accepted the resignations of Non-Executive Directors Mr. Michael Phelps, Mr. Patrick Kennedy and Dr. Franklyn Prendergast effective 29 August 2019.
Mr. Phelps and Mr. Kennedy and the Company have been discussing the creation of a new Growth & Advocacy Advisory Board for several months. Mr. Phelps and Mr. Kennedy will be the inaugural members of this Advisory Board which will be chaired by Mr. Peter Carlisle, Medibio’s Lead Non-Executive Director.
The newly created Growth & Advocacy Advisory Board is being formed to utilise the unique skill sets of Mr. Phelps and Mr. Kennedy to help advance awareness of Medibio’s mission and unique technology. Their unique capabilities are especially effective in reaching corporations, individuals and clinicians particularly as the company continues to commercialise its’ ilumen™ corporate wellbeing solution. This Growth & Advocacy Advisory Board will be independent of the Board of Directors and will work closely with Peter Carlisle and the Company’s management team to identify strategic opportunities to leverage the expertise, positioning and numerous connections of Mr. Phelps and Mr. Kennedy. “Medibio is doing important work in the area of mental health and its technology is now being used effectively to improve corporate wellbeing, through its ilumen™ product. I am excited to work with Patrick in this new role and to focus our efforts on increasing access to resources and technology that support improved mental health,” said Michael Phelps. Patrick Kennedy commented “I share Michael’s view of the importance of Medibio’s mission. I am thrilled to adapt my role with the Company to the Growth & Advocacy Advisory Board and look forward to working with Peter and Michael to assist the Company.”
Ms. Wipperman Heine is President and CEO of PreCardia, Inc., a St. Paul, Minnesota based early stage medical device company. Prior to joining PreCardia she held numerous executive management positions with large and small medical device and technology companies, primarily focused on clinical affairs, healthcare economics, policy and reimbursement and regulatory affairs. She serves on the Board of Directors of Natus Medical Incorporated (NASDAQ:NTUS) and the Board of Directors of Surmodics, Inc. (NASDAQ:SRDX).
Dr. Ide is the Chief Medical Officer of Zipnosis, a Minneapolis, Minnesota based leading virtual care software company that pairs traditional telemedicine with next-generation online virtual care tools, where she holds clinical and leadership roles in sales, digital health and directs the regulatory department reviewing state and federal telemedicine legislation. Prior to joining Zipnosis Dr. Ide held clinical and leadership roles in emergency medicine and corporate employee wellness and has expertise in telemedicine and health information technology. Dr. Ide is a member of numerous professional and industry associations in telemedicine and electronic healthcare.
Ms. Ojala is the Chief Executive Officer of CaringBridge, the first and most widely used global nonprofit social network dedicated to helping family and friends communicate with and support loved ones during any type of health journey. Prior to joining CaringBridge Ms. Ojala held technology executive positions establishing eCommerce platforms with a large retail company and smaller, high growth entrepreneurial companies. She is an attorney, having worked in both a large law firm and as legal counsel for a large publicly traded company, and remains a member of the Minnesota State Bar.
“I want to thank Michael Phelps, Patrick Kennedy and Franklyn Prendergast for their service to Medibio as Non-Executive Board members,” said David B. Kaysen, Chairman, Managing Director and CEO. “I am very excited to work with Michael, Patrick and Peter Carlisle in establishing our new Growth & Advocacy Advisory Board to utilise the unique impact Michael and Patrick can provide Medibio as we further expand our reach with ™.”
Kaysen went on to say, “Medibio is blessed to have attracted three incredible individuals to join our Board as Non-Executive Directors. Each of these new members bring a unique skill set that will assist us in moving Medibio forward in a positive, focused and strategic way. I welcome Ms. Wipperman Heine, Dr. Ide and Ms. Ojala to our Board. All of us at Medibio are excited to work closely with each of these highly qualified individuals.”
– ENDS –
About Medibio Limited Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic), and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Medibio Media Inquiries:
Director, Strategic Communications
T: +1 952 232 0934
T: +61 (0) 412 036 231